A new treatment option is now available for Canadian mothers struggling with postpartum depression. Health Canada has approved zuranolone,marketed as Zurzuvae,the first medication specifically designed for this condition,offering a perhaps faster path too relief than traditional therapies. The drug, already authorized in the US, UK, and EU, demonstrated significant symptom reduction within days in clinical trials, addressing a critical need given that approximately one in five women experience perinatal mood disorders [[1, 2, 3]].
Health Canada has approved the first medication specifically designed to treat postpartum depression, offering a potential new option for women experiencing mental health challenges after childbirth.
The medication, zuranolone, marketed under the name Zurzuvae, is a pill taken once daily for 14 days and has demonstrated the ability to begin alleviating depressive symptoms within just three days. This rapid onset of action is a key benefit for new mothers struggling with the condition.
Biogen, the manufacturer of Zurzuvae, received approval for the drug in the United States in late 2023, and it is also authorized for use in the United Kingdom and the European Union.
According to Health Canada, approximately one in five women experience depression or anxiety during or following pregnancy, highlighting the significant public health need for effective treatments.
Dr. Crystal Clark, a Canada Research Chair in Reproductive Mental Health and Associate Head of Research at the Women’s College Hospital, described zuranolone as a welcome advancement for women with moderate to severe postpartum depression.
Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for postpartum depression, but they typically take longer to show effects and require extended treatment periods, Dr. Clark explained.
“While we have effective treatments for many women experiencing postpartum depression, this medication will be the first to require only a two-week course and act quickly, within just a few days,” she noted.
SSRIs work by increasing the availability of serotonin, a neurotransmitter, in brain areas associated with mood regulation.
Zuranolone is a synthetic version of allopregnanolone, a metabolite of progesterone, a hormone that fluctuates significantly during pregnancy. The drug targets GABA (gamma-aminobutyric acid type A) receptors in the brain, which play a role in mood regulation.
Hormonal changes are closely linked to the development of postpartum depression symptoms, Dr. Clark added.
The medication is recommended for moderate to severe cases of postpartum depression, with severity assessed based on the degree to which daily functioning is impaired, according to Dr. Clark.
Symptoms
Symptoms of postpartum depression can include persistent feelings of sadness or significant mood swings, severe anxiety or panic attacks, intense irritability and anger, feelings of worthlessness, shame, or guilt, difficulty bonding with the baby, and overwhelming fatigue that extends beyond the typical sleep deprivation experienced by new parents.
Mothers experiencing postpartum depression may also exhibit changes in appetite, struggle with basic self-care tasks like showering or getting dressed, even with assistance, and in severe cases, may experience suicidal thoughts, Dr. Clark said.
Many of her patients with postpartum depression are “shocked to be having a problem.”
“I sometimes hear: ‘I wanted this pregnancy, I was looking forward to having this baby, I don’t understand why I feel so bad,’” she shared.
Clinical Trial Details
Health Canada conducted a thorough review of the evidence submitted by Biogen, confirming that the medication meets all safety, efficacy, and quality criteria, and that its benefits outweigh its risks when used as directed, according to a statement provided to The Canadian Press.
This evidence included a clinical trial that utilized the Hamilton Depression Rating Scale to measure symptom changes in 196 women with severe postpartum depression. Participants were randomly assigned to receive either zuranolone or a placebo once daily for 14 days.
The study revealed a “statistically significant” reduction in depressive symptoms among those taking the medication. The primary measurement was taken after two weeks of treatment, but some women experienced symptom improvement as early as three days after starting the drug.
Researchers followed up with participants 45 days later and found that symptom reductions were maintained.
The long-term effects and potential for symptom recurrence beyond this period are still unknown, Dr. Clark noted. However, she added that patients in the United States “are responding well” to the medication.
The most common side effects reported by participants in the study who took zuranolone were drowsiness, dizziness, sedation, and headache.
Women should avoid breastfeeding while taking the medication until further research determines its safety for infants, Dr. Clark advised.
Due to the potential for drowsiness, women are advised to have support during the initial days of treatment to assist with infant care while they assess their reaction to the medication, she added.
Dr. David Silver, a psychiatrist specializing in reproductive mental health at UPMC in Camp Hill, Pennsylvania, has been prescribing zuranolone for over a year and believes it is a “very important addition” to the treatment options available for postpartum depression due to its rapid action.
“When a woman has just given birth and needs to care for a newborn, every second counts,” he emphasized.
Dr. Silver explained that he assesses the depressive symptoms of his patients to determine whether an SSRI or zuranolone is the most appropriate treatment.
“If they have experienced multiple depressive episodes and their depression has persisted throughout their pregnancy, and didn’t just appear in the third trimester or immediately after delivery, then an SSRI may be beneficial,” he clarified.
“However, if a patient comes to me without having suffered from depression during her pregnancy and suddenly develops marked symptoms in the third trimester or just after delivery, then that’s when I seriously consider zuranolone,” he detailed.
